Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
Jürgen BehrAntje PrasseHubert WirtzDirk KoschelDavid PittrowMatthias HeldJens KlotscheStefan AndreasMartin ClaussenChristian GrohéHenrike WilkensLars HagmeyerDirk SkowaschJoachim F MeyerJoachim KirschnerSven GläserNicolas KahnTobias WelteClaus NeurohrMartin SchwaiblmairThomas BahmerTim OquekaMarion FrankenbergerMichael KreuterPublished in: The European respiratory journal (2020)
Survival was significantly higher in IPF patients with antifibrotic therapy, but the course of lung function parameters was similar in patients with and without antifibrotic therapy. This suggests that in clinical practice, premature mortality of IPF patients eventually occurs despite stable measurements for FVC and D LCO.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- interstitial lung disease
- end stage renal disease
- clinical practice
- newly diagnosed
- pulmonary fibrosis
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- free survival
- prognostic factors
- type diabetes
- stem cells
- risk factors